COVID-19 vaccine maker Moderna will more than double production and lab space at its technology centre in Norwood, Massachusetts, US, through renovation of existing space and the acquisition of a 2,223 m2 building located on the same campus.
The expansion of the Moderna Technology Center (MTC) will support a 50% increase in production of the company’s COVID-19 Vaccine, as well as other programs in its clinical development pipeline.
Moderna CEO Stéphane Bancel said the expanded facility would also help facilitate the company’s increased focus and investment in technical capabilities such as expansion of shelf-life stability and new pharmaceutical delivery forms such as prefilled syringes and lyophilized products.
“Our manufacturing facility has been core to our long-term strategy and has enabled us to provide the scale and flexibility to support the development of our mRNA medicines and vaccines including our COVID-19 vaccine,” Mr Bancel said.
“We believe that this investment and expansion at our technology centre will allow us to continue to optimize our mRNA products as we explore new pharmaceutical delivery forms such as prefilled syringes and lyophilized products.
“As we grow, we are committed to minimizing our environmental footprint.”
